ReviewVision (Basel, Switzerland)2025
Modifiable Lifestyle Risk Factors and Strategies for Slowing the Progression of Age-Related Macular Degeneration.
Review in Vision (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Mannose-modified miR-223 nanoparticles remodel pathological microenvironment to suppress inflammation and angiogenesis for neovascular AMD therapy.International journal of pharmaceutics: X · 2026Article
- Transition from intermediate to late AMD and associated changes in vision by two years in a multicentre cohort study in Europe- INTERCEPT-AMD Report 3.Eye (London, England) · 2026Article
- Bioactive Properties of Carotenoids in Ocular Diseases: Antioxidant, Anti-Inflammatory, and Neuroprotective Effects.Nutrients · 2026Review
- Update on the Management of ABCA4 Retinopathy (Stargardt Disease).Ophthalmology and therapy · 2026Review
- Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies.Ophthalmology. Retina · 2026Article
- An association between atrial fibrillation and age-related macular degeneration: looking beyond mere coincidence.Eye (London, England) · 2026Article
- The gut-retina axis in age-related macular degeneration: immune crosstalk and metabolite production.Experimental biology and medicine (Maywood, N.J.) · 2026Review
- Article
- The controversial role of nutraceuticals vs. drugs in proliferative retinopathies.Frontiers in neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration (AMD) is a multifactorial disorder influenced by genetic, lifestyle, nutritional, and systemic health factors that contribute to increased oxidative stress and chronic inflammation in the retina. This article reviews the recent literature on modifiable lifestyle risk factors for the development and progression of AMD. Smoking (current and former), physical inactivity, prolonged sunlight exposure, as well as conditions such as diabetes, hypertension, cardiovascular disease, and obesity have all been associated with an increased risk of early AMD and its progression. The Age-Related Eye Disease Studies (AREDS and AREDS2) have shown that a specific combination of vitamins E and C, zinc, copper, lutein, and zeaxanthin can significantly reduce the risk of AMD progressing from dry to wet form. Additionally, adherence to a Mediterranean diet, rich in vegetables, fruits, legumes, whole grains, and nuts, has been linked to a lower risk of both early and late AMD. Emerging evidence suggests that these benefits may be influenced by the gut microbiota, as well as genetic and epigenetic factors. Further research into the interactions between these risk factors could pave the way for targeted therapies aimed at preventing or slowing AMD progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.